Suppr超能文献

膜联蛋白和生存素在局部晚期直肠癌中的作用:术前放化疗耐药的指标?

Annexin and survivin in locally advanced rectal cancer: indicators of resistance to preoperative chemoradiotherapy?

作者信息

Horisberger Karoline, Erben Philipp, Ströbel Philipp, Bohn Beatrice, Hahn Melanie, Kähler Georg, Wenz Frederik, Hochhaus Andreas, Post Stefan, Willeke Frank, Hofheinz Ralf-Dieter

机构信息

Chirurgische Klinik, Universität Heidelberg, Heidelberg, Germany.

出版信息

Onkologie. 2010;33(8-9):439-44. doi: 10.1159/000318145. Epub 2010 Jul 22.

Abstract

BACKGROUND

The aim of preoperative chemoradiotherapy is improvement of local control in patients with locally advanced rectal cancer (LARC). Recent studies have shown that annexin and survivin are involved in the resistance capability of tumours. We sought to determine whether survivin, annexin A4 or annexin A5 expression predict resistance to preoperative chemoradiotherapy.

MATERIAL AND METHODS

Biopsies of tumour and normal rectal tissue were taken from 38 patients with LARC (cT3/4Nx or Tx/N+) before the start of chemoradiotherapy and during surgery. mRNA expression of annexin A4/A5 and survivin was measured by real-time polymerase chain reaction (RT-PCR) and correlated with down-staging and progression-free survival (PFS).

RESULTS

Significantly higher mRNA levels of survivin, and annexin A4/A5 were detected in untreated tumour compared with normal mucosa. After chemoradiotherapy, this difference disappeared for survivin and annexin A4. Annexin A5 expression in the tumour increased during chemoradiotherapy. No correlation between the mRNA levels of survivin, annexin A4/A5 and tumour down-staging or PFS was noticed.

CONCLUSIONS

In the present analysis of 38 patients with LARC undergoing neoadjuvant chemoradiotherapy, the expression levels of survivin and annexin A4 and A5 did not correlate with down-staging. Moreover, with regard to PFS, none of these markers was found to be prognostically relevant.

摘要

背景

术前放化疗的目的是提高局部晚期直肠癌(LARC)患者的局部控制率。最近的研究表明,膜联蛋白和生存素与肿瘤的耐药能力有关。我们试图确定生存素、膜联蛋白A4或膜联蛋白A5的表达是否可预测对术前放化疗的耐药性。

材料与方法

在放化疗开始前及手术期间,从38例LARC患者(cT3/4Nx或Tx/N+)获取肿瘤及正常直肠组织活检样本。通过实时聚合酶链反应(RT-PCR)检测膜联蛋白A4/A5和生存素的mRNA表达,并将其与降期和无进展生存期(PFS)相关联。

结果

与正常黏膜相比,未经治疗的肿瘤中生存素以及膜联蛋白A4/A5的mRNA水平显著更高。放化疗后,生存素和膜联蛋白A4的这种差异消失。放化疗期间肿瘤中膜联蛋白A5的表达增加。未发现生存素、膜联蛋白A4/A5的mRNA水平与肿瘤降期或PFS之间存在相关性。

结论

在目前对38例接受新辅助放化疗的LARC患者的分析中,生存素、膜联蛋白A4和A5的表达水平与降期无关。此外,就PFS而言,未发现这些标志物中的任何一个具有预后相关性。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验